Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC. - Selke, Janne; Dzierma, Yvonne; Manda, Katrin; Hildebrandt, Guido; Frerker, Bernd; Kalata, Paul; Ackermann, Christin; Bock, Felix (Current Oncology, 2026)